Answers are grounded in this paper and cite their sources.
SIR—Attassi et al. [1] raise concerns that the incidence of thrombocytopenia associated with administration of linezolid may be higher than the 3% incidence previously reported by the manufacturer [2]. In addition, the authors propose that the risk for thrombocytopenia may occur earlier than the 2-week time frame after which the manufacturer recommends monitoring of platelet counts in patients who do not have other risk factors for thrombocytopenia. We would like to describe our experience with treating patients with linezolid, because we have also seen a higher-than-reported incidence of thrombocytopenia. Shands Hospital at the University of Florida is a 576-bed university teaching hospital in Gainesville. Since linezolid received US Food and Drug Administration approval, the use of this drug has been restricted at our institution, and all use requires prior approval of the Infectious Diseases Service. Linezolid use is limited to the treatment of serious infections caused by gram-positive organisms that are resistant to other therapies (e.g., vancomycin-resistant enterococci) and treatment of patients who are intolerant to other drugs (e.g., patients infected with methicillin-resistant Staphylococcus aureus who cannot tolerate vancomycin). Since May 2000, a total of 71 patients at our institution have received linezolid for durations ranging from 1 to 44 days. Forty-eight patients received therapy for ⩾5 days. Thrombocytopenia, defined as a decrease in platelet count of ⩾30%, occurred in 23 (48%) of 48 patients, with a range of decrease of 32%–89%. This incidence of thrombocytopenia is similar to the 47% incidence reported by Attassi et al. [1]. In our patients, a decrease in platelet count to <100,000 cells/mm3 occurred in 9 (19%) of 48 patients, compared with the 32% incidence reported by Attassi et al. [1]. In contrast to Attassi et al. [1], we have seen a similar median duration of therapy for patients who developed thrombocytopenia (median, 12 days; range, 5–34 days) and patients who did not develop thrombocytopenia (median, 12 days; range, 5–44 days). Attassi et al. [1] reported a longer duration of therapy for patients who developed thrombocytopenia (median, 19.1 days; range, 10–42 days) than for patients who did not develop thrombocytopenia (median, 7.7 days; range, 5–11 days). It is clear that the incidence of thrombocytopenia associated with linezolid therapy is much higher than the 3% incidence found in clinical trials reported by the manufacturer in the product information [2]. It is likely that restricting the use of this agent has resulted in selection of a population of patients who are inherently sicker, and thus more prone to hematologic abnormalities, than those included in the clinical trials. Because thrombocytopenia has occurred with a median duration of therapy of <14 days, clinicians should begin monitoring platelet counts <14 days after initiation of treatment. We recommend at least weekly monitoring of platelet counts in all patients receiving linezolid therapy. A thorough evaluation of the risk factors for thrombocytopenia associated with linezolid therapy should be performed, to determine whether select patient groups can be targeted for more- or less-intense monitoring of platelet counts.
No takes yet. Share an insight, caveat, or question.
Orrick et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: